Integral Health Asset Management LLC Purchases New Holdings in Pharvaris N.V. $PHVS

Integral Health Asset Management LLC bought a new stake in Pharvaris N.V. (NASDAQ:PHVS) during the third quarter, HoldingsChannel.com reports. The institutional investor bought 200,000 shares of the company’s stock, valued at approximately $4,990,000.

Other large investors also recently bought and sold shares of the company. JPMorgan Chase & Co. increased its stake in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the period. HighVista Strategies LLC lifted its holdings in Pharvaris by 4.3% in the second quarter. HighVista Strategies LLC now owns 23,739 shares of the company’s stock valued at $418,000 after acquiring an additional 971 shares during the period. California State Teachers Retirement System grew its position in Pharvaris by 9.8% during the second quarter. California State Teachers Retirement System now owns 14,048 shares of the company’s stock worth $247,000 after buying an additional 1,257 shares during the period. Legal & General Group Plc boosted its stake in shares of Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares in the last quarter. Finally, Palumbo Wealth Management LLC grew its holdings in shares of Pharvaris by 14.4% in the 3rd quarter. Palumbo Wealth Management LLC now owns 16,641 shares of the company’s stock worth $415,000 after acquiring an additional 2,092 shares during the period.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Wall Street Zen cut Pharvaris from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research report on Thursday, January 22nd. Oppenheimer raised their price target on Pharvaris from $44.00 to $50.00 and gave the stock an “outperform” rating in a research report on Thursday, December 4th. Leerink Partners set a $38.00 price objective on Pharvaris in a research report on Wednesday, December 3rd. Finally, Morgan Stanley increased their price objective on Pharvaris from $37.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, December 4th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $41.70.

Pharvaris Trading Down 3.6%

Shares of PHVS stock opened at $25.42 on Friday. The firm’s 50-day simple moving average is $26.69 and its 200-day simple moving average is $24.97. Pharvaris N.V. has a 1-year low of $11.51 and a 1-year high of $29.80.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.